胸腺肽α_1联合拉米夫定治疗慢性乙型病毒性肝炎的疗效观察

Curative effectivenss of lamivudine combined with thymosin α_1 in the treatment of chronic hepatitis B

目的观察胸腺肽α1(迈普新)联合拉米夫定治疗慢性乙型病毒性肝炎的疗效。方法选择慢性乙型病毒性肝炎患者70例,随机分为联合组(35例)和对照组(35例)。对照组给予拉米夫定100mg口服,每日1次,疗程12个月,同时口服葡醛内酯(肝泰乐)、肌苷片等。联合组在上述基础上采用迈普新1.6mg皮下注射,每周2次,共用6个月。结果治疗6个月、12个月及停药后观察6个月,两组ALT复常率、HBV-DNA转阴率无显著性差异,但在HBeAg转阴率及HBeAg/HBeAb血清转换率方面,联合组在治疗12个月及随访6个月时均显著高于对照组(P<0.05)。结论胸腺肽α1(迈普新)联合拉米夫定可提高治疗慢性乙型病毒性肝炎的疗效。

Objective To observe the curative effectiveness of thymosin α1 combined with lamivudine in the treatment of chronic hepatitis B. Methods Seventy patients with chronic hepatitis B were randomly divided into treatment group （35 cases） and control group （35 cases）. Lamivudine was administrated orally with 100 rag per day for 12 months, as well as other treatments in control group. Treatment group was given with hypodermic injection of thymosin-α1 , twice a week for 6 months besides lamivudine treatment. Results On the 6th, 12th month after treatment, and 6th month after drug withdrawal, there was no significant difference in the recovery rate of ALT and the clearance rate of HBV-DNA between two, but the clearance rate of HBeAg and HBeAg/HBeAb was significantly different between two groups on the 12th month after tretments and 6th month after drug withdrawal. Conclusion The treatment of thymosin al combined with lamivudine for chronic hepatitis B can improve the outcomes.